Dec. 1976

Diazepines I. A New Synthesis of 6-Phenyl-4*H*-imidazo[1,2-*a*][1,4] benzodiazepines

Takeshi Hara, Kazuhiko Itoh and Nobuhiro Itoh

Teijin Institute for Biomedical Research, 4-3-2 Asahigaoka, Hino, Tokyo 191, Japan Received July 26, 1976

6-Phenyl-4H-imidazo[1,2-a][1,4]benzodiazepines are obtained on reaction of 2-amino-7-chloro-5-phenyl-3H-1,4-benzodiazepine with α -bromoketones. In the cases of 3-bromo-2-butanone and of 3-bromo-2-pentanone, 2-alkylimidazobenzodiazepine but not 1,2-dialkyl compound is the major product. A mechanism for the imidazole ring formation is presented.

J. Heterocyclic Chem., 13, 1233 (1976).

Considerable attention has been directed in recent years to the synthesis of tricyclic diazepine compounds possessing useful anxiolytic activity (1,2). This paper describes a new synthesis of 6-phenyl-4H-imidazo[1,2-a]-[1,4]benzodiazepines (2) by the action of the amidine moiety of the 2-aminobenzodiazepine 2 with α -bromoketones. Although this type of reaction for the formation of imidazole ring has been known for many years (3), it has not yet been studied in detail, particularly with respect

RCOCH₂Br

2

RCOCH₂Br

CI

2
$$\xrightarrow{\text{CH}_3\text{COCHR}}$$
 3b or 3c + CI $\xrightarrow{\text{R}^0}$ 0 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 0 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 2 $\xrightarrow{\text{R}^0}$ 2 $\xrightarrow{\text{R}^0}$ 2 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 2 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 4 $\xrightarrow{\text{R}^0}$ 5 $\xrightarrow{\text{R}^0}$ 6 $\xrightarrow{\text{R}^0}$ 6 $\xrightarrow{\text{R}^0}$ 8 $\xrightarrow{\text{R}^0}$ 7 $\xrightarrow{\text{R}^0}$ 9 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 1 $\xrightarrow{\text{R}^0}$ 2 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 2 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 2 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 3 $\xrightarrow{\text{R}^0}$ 5 $\xrightarrow{\text{R}^0}$ 6 $\xrightarrow{\text{R}^0}$ 7 $\xrightarrow{\text{R}^0}$ 9 $\xrightarrow{\text{R$

to N-substituted amidine (viz. 1).

The 2-aminobenzodiazepine 2 (4) was heated with bromoacetone in ethanol to give the imidazobenzodiazepine 3a (Scheme I). Even if one reasonably assumes that the nitrogen atom which makes a nucleophilic attack on bromoacetone is that of the 2-amino group, there are still two possible structures 3a and 4 for the product imidazobenzodiazepine, corresponding to two possible sites of attack, namely the carbonyl group and the α -carbon atom. The reaction product was determined to be 3a but not 4 through the comparison of the nmr spectrum of the product with that of 4 prepared according to reported procedure (2b), treating the thioamide 5 with propargylamine in the presence of p-toluenesulfonic acid. The

imidazole ring proton of 3a (C_1 -H) resonates at a lower magnetic field than that (C_2 -H) of 4 (δ 7.05 vs. 6.83), and regarding the methyl proton signal the opposite is observed (δ 2.25 vs. 2.35). These can be attributed to the anisotropic deshielding effect of the benzene ring of the benzodiazepine skeleton on C_1 -H and C_1 -CH₃. Similarly are prepared the imidazobenzodiazepines 3b,c,d,e. In the nmr spectra of all of these imidazobenzodiazepines 3a-e, the methylene protons of the diazepine ring exhibit two

broad singlets at ambient temperature, whereas, those of 4 show a clear AB quartet. Examination of molecular model suggests that this contrast is due to the fact that whereas, in the case of 4, there is steric interaction between the 1-substituent with the hydrogen atom of the benzene ring, the compounds 3a-e have no such steric interaction making the seven-membered ring of 3a-e more flexible than that of 4. Thus, examination of the methylene proton signals contributes to the determination of the position of the substituent on the imidazole ring.

In order to synthesize 1,2-dialkyl-6-phenyl-4*H*-imidazo-[1,2-a][1,4]benzodiazepines, **2** was treated with 3-bromo-2-butanone and with 3-bromo-2-pentanone. Although the reactions afforded the expected **6a,b** (Scheme I), the major products were **3b** and **3c**. As in the case of **4**, the methylene protons of the diazepine ring of **6a,b** exhibited, in the nmr spectra, a clear AB quartet supporting the existence of a substituent at the 1-position. Isomerization of 3-bromo-2-butanone to 1-bromo-2-butanone by the aid of a basic substance prior to the reaction with **2** is excluded by the experiments where 3-bromo-2-butanone

was heated with triethylamine and with 1,5-diazabicyclo-[5.4.0]undec-5-ene (DBU) in refluxing ethanol; the gas chromatographic analysis of the mixture did not detect any 1-bromo-2-butanone.

A possible mechanistic sequence (Scheme II) for the imidazole ring formation is one in which the 2-amino group of aminobenzodiazepine 2 reacts with the carbony! group of α-bromoketone to form the shiff-base 7, which then cyclizes with loss of hydrogen bromide to give 9 and/or 10 with 8 (5) as the probable intermediate. Tautomerization of 9 and 10 gives 11 and 12, respectively. This sequence accounts for the formation of 3b [12](R = $H, R' = CH_3$ and **3c** [12 (R = H, R' = C_2H_5)] together with 6a [11 (R = H, R' = CH_3)] and 6b [11 (R = H, R' = C₂H₅)], respectively in the reaction of 2 with 3-bromo-2-butanone and with 3-bromo-2-pentanone, respectively. In the case where the formation of two isomeric imidazobenzodiazepines is possible, such isomer as having no or a smaller substituent at the 1-position is predominant because of the steric interaction, at the transition state of the conversion of 8 to 9 or 10, of the potential 1-substituent with the hydrogen atom on the 9-position of the starting aminobenzodiazepine. In other words, the nitrogen atom of the seven-membered ring attacks preferentially the carbon atom having no or a smaller substituent [the conversion (a) (Scheme II) predominates when R' < R, whereas the conversion (b) when R < R']. The above reasoning is supported by the experimental observation that the product ratio of 3c and 6b (4.6:1) (Experiment number 7, Table 1) is larger than that of 3b and 6a (2.3:1) (Experiment number 6, Table I).

EXPERIMENTAL

Melting points were taken on a Yanagimoto hot-stage apparatus and are uncorrected. Instrumental data were obtained from Hitachi EPI-510 infrared spectrophotometer, a Varian EM 360 nuclear magnetic resonance spectrometer except in the case otherwise noted with tetramethylsilane as an internal standard, and a LKB 9000 mass spectrometer.

General Procedure for 6-Phenyl-4/I-imidazo[1,2-a][1,4]benzo-diazepines.

A mixture of $4.0 \sim 8.4$ mmoles of 2-amino-7-chloro-5-phenyl-3H-1,4-benzodiazepine (4), α -bromoketone, and ethanol was heated at reflux. The solvent was evaporated under reduced pressure, and to the residual material were added ethyl acetate (or methylene chloride) and water. Without separating two layers, the water layer was made alkaline with saturated aqueous sodium bicarbonate solution. The separated organic layer was washed with water and dried over anhydrous sodium sulfate. The material obtained on evaporation of the solvent was chromatographed on silica gel with benzene-ethyl acetate as the cluant. Imidazobenzodiazepine thus obtained was recrystallized from organic solvent. The more detailed reaction conditions and the product(s) are listed in Table I, and the melting points and the analytical data of the 6-phenyl-4H-imidazo[1,2-a][1,4]benzodiazepines are shown in Table II.

The spectral data are written below.

8-Chloro-2-methyl-6-phenyl-4H-imidazo[1,2-a][1,4] benzodiazepine (3a).

Ir (potassium bromide) cm $^{-1}$: 1604, 1575, 1526, 1486, 1445, 1430, 1313, 1299; nmr (deuteriochloroform) δ : 2.25 (3H, s, CH₃), 4.4 (1H, broad s) and 5.1 (1H, broad s) (CH₂N), 7.05 (1H, s, -CH=), 7.15-7.85 (8H, m, C₆H₅ and C₆H₃).

8-Chloro-2-ethyl-6-phenyl-4H-imidazo[1,2-a][1,4] benzodiazepine (3b).

Ir (potassium bromide) cm $^{-1}$: 1613, 1575, 1525, 1487, 1445, 1429, 1315, 1305; nmr (deuteriochloroform) δ : 1.25 (3H, t, J = 7.4 Hz, CH₃), 2.64 (2H, q, J = 7.4 Hz, CH₂CH₃), 4.2 (1H, broad s) and 5.1 (1H, broad s) (CH₂N), 7.07 (1H, s, -CH=), 7.16-7.7 (8H, m, C₆H₅ and C₆H₃).

Table I

Synthesis of 6-Phenyl-4*H*-imidazo[1,2-a][1,4]benzodiazepines

Product **Reaction Conditions** R' Yield R Molar Ratio of Reaction α -Bromoketone Experiment (%) Period employed α-Bromoketone/ Number Aminobenzo-(hours) diazepine CH_3 22 Н 3a CH₃COCH₂Br 1.2 23 1 CH₂CH₃ 35 3b Н 5 2 CH3CH2COCH2Br 6 CH2CH2CH3 14 $CH_{3}CH_{2}CH_{2}COCH_{2}Br$ 3с Н 4 3.8 3 20 $CH(CH_3)_2$ 3d 5 5 Н 4 (CH₃)₂CHCOCH₂Br CH₂C₆H₅ 20 3e 4 Н 5 $C_6H_5CH_2COCH_2Br$ 3 7 3b Н CH₂CH₃ 12 CH₃COCHBrCH₃ 6 5.2 6a CH_3 CH_3 CH2CH2CH3 13 5 3с Η CH₃COCHBrCH₂CH₃ 3 7 2.8 CH₂CH₃ CH₃ 6b

Table II

Physical and Analytical Data for 6-Phenyl-4H-imidazo[1,2-a][1,4] benzodiazepines

| Compound Number | M.p. (°C) (Recrystallization solvent) (a) | Formula | Anal. | C (%) | H (%) | N (%) | Mass Spec. | M ⁺ , m/e |
|--------------------|---|---------------------|-----------------|------------------|--------------|------------------|-----------------|-------------------------------------|
| 3 a | 174-176 (B-H) | $C_{18}H_{14}CIN_3$ | Calcd. Found | $70.24 \\ 70.30$ | 4.59 4.39 | $13.69 \\ 13.27$ | | |
| 3b | 147-149 (A-H) | $C_{19}H_{16}CIN_3$ | Calcd. Found | 70.91 71.09 | 5.02 4.83 | $13.06 \\ 12.74$ | Calcd. Found | 321.10333 321.10381 ± 0.00963 |
| 3c | 158-159 (B-H) | $C_{20}H_{18}CIN_3$ | Calcd. Found | 71.53 71.56 | 5.40 5.48 | $12.51 \\ 12.29$ | Calcd. Found | 335.11899 335.11810 ± 0.01005 |
| 3d | 138-140 (B-H) | $C_{20}H_{18}CIN_3$ | Calcd. Found | 71.53 71.81 | 5.40 5.49 | $12.51 \\ 12.23$ | Calcd. Found | 335.11899 335.11580 ± 0.01005 |
| 3 e | 143-145 (A-H) | $C_{24}H_{18}CIN_3$ | Calcd. Found | 75.09 74.77 | 4.73 4.63 | 10.95 10.98 | Calcd. Found | 383.11899 383.11924 ± 0.01149 |
| 6a | 152-153 (B-H) | $C_{19}H_{16}CIN_3$ | Calcd. Found | 70.91 70.80 | 5.02 4.78 | $13.06 \\ 12.68$ | Caled. Found | 321.10333 321.10480 ± 0.00963 |
| 6 b | 136-137 (B-H) | $C_{20}H_{18}CIN_3$ | | | | | Caled. Found | 335.11899 335.11780 ± 0.01005 |

⁽a) B-H = benzene-n-hexane, A-H = ethyl acetate-n-hexane.

8-Chloro-6-phenyl-2-propyl-4H-imidazo[1,2-a][1,4] benzodiazepine (3c).

Ir (potassium bromide) cm⁻¹: 1609, 1571, 1522, 1488, 1445, 1429, 1316, 1304; nmr (deuteriochloroform) δ : 1.00 (3H, t, J = 7.0 Hz, CH₃), 1.74 (2H, sextet, J = 7.0 Hz, CH₂CH₃), 2.63 (2H, J = 7.0 Hz, CH₂CH₂CH₃), 4.25 (1H, broad s) and 5.20 (1H, broad s) (CH₂N), 7.12 (1H, s, -CH=), 7.33-7.6 (8H, m, C₆H₅ and C₆H₃).

8-Chloro-2-isopropyl-6-phenyl-4H-imidazo[1,2-a][1,4]benzodiazepine (**3d**).

Ir (potassium bromide) cm $^{-1}$: 1608, 1596, 1576, 1552, 1486, 1469, 1449, 1428, 1384; nmr (deuteriochloroform) (6) δ : 1.26 (6H, d, J = 6.0 Hz, 2 x CH₃), 2.90 (1H, apparent quintet, J = 6.0 Hz, CH(CH₃)₂), 4.2 (1H, broad s) and 5.1 (1H, broad s) (CH₂N), 7.01 (1H, s, -CH=), 7.2-7.6 (8H, m, C₆H₅ and C₆H₃).

2-Benzyl-8-chloro-6-phenyl-4H-imidazo[1,2a][1,4]benzodiazepine (**3e**).

Ir (potassium bromide) cm $^{-1}$: 1608, 1572, 1523, 1485, 1444, 1425, 1312; nmr (deuteriochloroform) δ : 3.95 (2H, s, $CH_2C_6H_5$), 4.25 (1H, broad s) and 5.15 (1H, broad s) (CH $_2N$), 6.90 (1H, s, -CH=), 7.0-7.9 (13H, m, 2 x C_6H_5 and C_6H_3).

8-Chloro-1,2-dimethyl-6-phenyl-4H-imidazo[1,2-a][1,4]benzo-diazepine (6a).

Ir (potassium bromide) cm $^{-1}\colon 1607,\,1572,\,1525,\,1485,\,1443,\,1419,\,\,1315;\,\,$ nmr (deuteriochloroform) $\delta\colon \,\,2.18$ (3H, s, 2-CH₃), 2.28 (3H, s, 1-CH₃), ν_A 5.30 and ν_B 3.98 (2H, AB system, J = 14 Hz, CH₂N), 7.3-7.6 (8H, m, C₆H₅ and C₆H₃).

8-Chloro-1-ethyl-2-methyl-6-phenyl-4*H*-imidazo[1,2-a][1,4]benzo-diazepine (**6b**).

Ir (potassium bromide) cm⁻¹: 1605, 1555, 1525, 1480, 1415, 1310; nmr (deuteriochloroform) δ : 0.99 (3H, t, J = 8 Hz, CH₂CH₃), 2.25 (3H, s, 2-CH₃), 2.80 (2H, t, J = 8 Hz, CH₂CH₃), ν_A 5.25 and ν_B 3.97 (2H, AB system, J = 13 Hz, CH₂N), 7.2-7.7 (8H, m, C₆H₅ and C₆H₃).

Acknowledgment.

The authors wish to thank Misses K. Tatebe and M. Sasaki for microanalyses, Mr. M. Asano for mass spectra and Dr. T. Wakabayashi for valuable discussion. Particular appreciation is expressed to Dr. T. Noguchi, Dr. S. Tsunoda and Mr. S. Ishimoto for their advice and support during the course of this investigation.

REFERENCES AND NOTES

- (1a) J. B. Hester, Jr., A. D. Rudzik and B. V. Kamdar, *J. Med. Chem.*, 14, 1078 (1971); (b) K. Megro, H. Tawada and Y. Kuwada, *Chem. Pharm. Bull.*, 21, 1619 (1973).
- (2a) J. B. Hester, Jr. and A. R. Hanze (to Upjohn), U.S. Patent 3,917,627 (1975); (b) (to Centre d'Etudes pour l'Industrie Pharmaceutique), German Patent 2,321,705 (1973).
- (3) K. Hofmann, "The Chemistry of Heterocyclic Compounds. Imidazole and Its Derivatives," Part I, Interscience Publishers, Inc., New York, N. Y., 1953, p. 43.
- (4) K. Megro, H. Tawada and Y. Kuwada, Yakugaku Zasshi 93, 1253 (1973).
- (5) The process from the deprotonation from the CH_2R group of 7 to the five-membered ring formation may be concerted. The

possibility that the species 13 is the intermediate is excluded by the observation that 6a was not obtained by the reaction of 2 with 1-bromo-2-butanone and that 6b by the reaction with 1-bromo-2-pentanone.

(6) The spectrum was recorded on a JEOL JNM-MH-100 spectrometer.